Showing 8601-8610 of 9547 results for "".
- Researchers Uncover Clues Driving PsO Spread and Severityhttps://practicaldermatology.com/news/researchers-uncover-clues-driving-pso-spread-and-severity/2461759/New research sheds light on the cellular changes that drive psoriasis severity and also offers important clues about how the disease spreads to other parts of the body. Specifically, the location of clusters of fibroblasts and macrophages tend to occur more commonly in the upper l
- TWi Biotechnology, Yale University Seek Participants With GA for Phase 1 trial of a Topical JAK Inhibitorhttps://practicaldermatology.com/news/twi-biotechnology-yale-university-seek-participants-with-ga-for-phase-1-trial-of-a-topical-jak-inhibitor/2461757/TWi Biotechnology (TWiB) is seeking participants for a Phase 1 clinical trial of a topical gel form of tofacitinib for the treatment of granuloma annulare (GA). Individuals with GA or friends and family members can find study information at:
- Scientists Identify Genomic Cause and Potential Treatment for Disabling Pansclerotic Morpheahttps://practicaldermatology.com/news/scientists-identify-genomic-cause-and-potential-treatment-for-disabling-pansclerotic-morphea/2461756/Researchers have identified genomic variants that cause disabling pansclerotic morphea and have found a potential treatment. People with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug tha
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults wit
- DermBiont's 0.8% SM-030 Topical Gel Fades Solar Lentigos, Normalizes Pigmentation in Phase 2 Studyhttps://practicaldermatology.com/news/dermbionts-08-sm-030-topical-gel-fades-solar-lentigos-normalizes-pigmentation-in-phase-2-study/2461748/DermBiont’s 0.8% SM-030 gel performed well in a Phase 2 trial treating solar lentigos and normalizing pigmentation of the skin, the Company reports. SM-030 is a first-in-class selective and potent topical PKCβ inhibitor intended to reduce the production of epidermal mela
- PsO Pipeline Update: First Cohort of Patients Dosed with LNK01004 in Phase Ib Studyhttps://practicaldermatology.com/news/pso-pipeline-update-first-cohort-of-patients-dosed-with-lnk01004-in-phase-ib-study/2461742/The first cohort of psoriatic patients have been dosed in a Phase Ib clinical trial of Lynk Pharmaceuticals Co., Ltd.’s LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese p
- Call for Papers: JMIR Dermatology Special Theme Issue on Teledermatologyhttps://practicaldermatology.com/news/call-for-papers-jmir-dermatology-special-theme-issue-on-teledermatology/2461734/JMIR Dermatology—the official journal of the International Society of Teledermatology (ISTD)—and the journal’s guest editors welcome submissions to
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres
- FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancerhttps://practicaldermatology.com/news/fda-greenlights-phio-pharmaceuticals-trial-of-ph-762-in-skin-cancer/2461721/The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer. PH-762 is an INTASYL compound
- La Roche-Posay Gives Back: Brand Offers Free Public Screenings in NYChttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-offers-free-public-screenings-in-nyc/2461678/La Roche-Posay is kicking off Melanoma Awareness Month with free public skin cancer screenings at Hudson Yards on Sunday, April 30th and Monday, May 1st. On Sunday, April 30th and Monday, May 1st (Melanoma Monday,) La Roche-Posay, in partners